Biopharma news, November 21, 2026
1 story
In this digest: Regulatory setback 1
Top story
FDA Rejects Deramiocel Application
The FDA issued a complete response letter for Capricor's resubmitted deramiocel biologics license application, finding insufficient evidence of effectiveness and citing other clinical deficiencies. Capricor said the HOPE-2 and HOPE-3 trials both met their primary endpoints and is reviewing the letter before announcing next steps. The company reported approximately $198.5 million in cash and securities as of September 30, 2026, and scheduled a conference call for November 23.
Source types: Press release
Sources are available to Gosset users. Log in to see them.
All digests
- November 20, 2026 5 stories
- November 19, 2026 6 stories
- November 18, 2026 5 stories
- November 17, 2026 5 stories
- November 16, 2026 3 stories
- November 15, 2026 4 stories
- November 14, 2026 5 stories
- November 13, 2026 5 stories
- November 12, 2026 10 stories
- November 11, 2026 10 stories
- November 10, 2026 10 stories
- November 9, 2026 10 stories
- November 8, 2026 9 stories
- November 7, 2026 7 stories
- November 6, 2026 10 stories
- November 5, 2026 10 stories